US 11,780,835 B2
Pyrazolo[3,4-b]pyridine compounds as inhibitors of TAM and MET kinases
Ronald Jay Hinklin, Boulder, CO (US); Shelley Allen, Boulder, CO (US); Patrick Barbour, Boulder, CO (US); Adam Cook, Boulder, CO (US); Joshua Dahlke, Boulder, CO (US); John Gaudino, Boulder, CO (US); Ellen Laird, Boulder, CO (US); Oren T. McNulty, Boulder, CO (US); and Qian Zhao, Boulder, CO (US)
Assigned to Array BioPharma Inc., Boulder, CO (US)
Filed by Array BioPharma Inc., Boulder, CO (US)
Filed on Jul. 15, 2021, as Appl. No. 17/376,571.
Application 17/376,571 is a division of application No. 16/555,432, filed on Aug. 29, 2019, granted, now 11,104,676.
Claims priority of provisional application 62/858,686, filed on Jun. 7, 2019.
Claims priority of provisional application 62/724,829, filed on Aug. 30, 2018.
Prior Publication US 2023/0011441 A1, Jan. 12, 2023
Int. Cl. C07D 471/04 (2006.01)
CPC C07D 471/04 (2013.01) 9 Claims
 
1. A method for treating cancer in a patient in need thereof, the method comprising administering to the patient a therapeutically effective amount of (R)—N-(3-fluoro-4-((3-((1-hydroxypropan-2-yl)amino)-1H-pyrazolo[3,4-b]pyridin-4-yl)oxy)phenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide having the structure

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof.